Rivastigmine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
Rivastigmine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | |
Rivastigmine | hsa00830 | Retinol metabolism | 3.49E-02 | 1 | P00325 | ADH1B | More | |
Rivastigmine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
Rivastigmine | hsa03010 | Ribosome | 1.53E-05 | 8 | P62753, P62906, P46776, Q07020, P61513, P27635, P62249, P23396 | RPS6, RPL10A, RPL27A, RPL18, RPL37A, RPL10, RPS16, RPS3 | More | |
Rivastigmine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Rivastigmine | hsa03040 | Spliceosome | 1.46E-02 | 4 | P17844, P51991, P61978, P11142 | DDX5, HNRPA3, HNRPK, HSPA8 | More | |
Rivastigmine | hsa04014 | Ras signaling pathway | 4.65E-02 | 3 | Q15311, P0DP23, P17612 | RALBP1, CALM1, PRKACA | More | |
Rivastigmine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | |
Rivastigmine | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | |
Rivastigmine | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | |
Rivastigmine | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | |
Rivastigmine | hsa04114 | Oocyte meiosis | 2.15E-02 | 3 | P0DP23, P17612, Q13362 | CALM1, PRKACA, PPP2R5C | More | |
Rivastigmine | hsa04141 | Protein processing in endoplasmic reticulum | 2.82E-04 | 8 | P18848, Q15437, Q15436, Q99941, P11142, P07900, Q9NR31, P14625 | ATF4, SEC23B, SEC23A, CREBL1, HSPA8, HSP90AA1, SAR1A, HSP90B1 | More | |
Rivastigmine | hsa04144 | Endocytosis | 4.07E-03 | 5 | Q9H444, O75351, P42566, Q15438, Q14161 | CHMP4B, VPS4B, EPS15, PSCD1, GIT2 | More | |
Rivastigmine | hsa04151 | PI3K-Akt signaling pathway | 4.12E-04 | 9 | P62753, P27348, P07900, P14625, Q16363, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, HSP90B1, LAMA4, TNXB, CREBL1, ATF4, SGK | More | |
Rivastigmine | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Rivastigmine | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | |
Rivastigmine | hsa04217 | Necroptosis | 4.56E-03 | 4 | P23458, Q9NQC7, Q9H444, O75351 | JAK1, CYLD, CHMP4B, VPS4B | More | |
Rivastigmine | hsa04261 | Adrenergic signaling in cardiomyocytes | 9.60E-04 | 7 | P51828, P17612, Q99941, P18848, Q13362, P0DP23, Q13557 | ADCY7, PRKACA, CREBL1, ATF4, PPP2R5C, CALM1, CAMK2D | More | |
Rivastigmine | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
Rivastigmine | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | |
Rivastigmine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.48E-03 | 8 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3 | More | |
Rivastigmine | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | |
Rivastigmine | hsa04659 | Th17 cell differentiation | 1.25E-03 | 8 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | |
Rivastigmine | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | |
Rivastigmine | hsa04713 | Circadian entrainment | 4.42E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Rivastigmine | hsa04714 | Thermogenesis | 6.01E-04 | 8 | Q16539, P51828, P62753, P33121, P12074, O15239, Q16718, O14521 | MAPK14, ADCY7, RPS6, ACSL1, COX6A1, NDUFA1, NDUFA5, SDHD | More | |
Rivastigmine | hsa04720 | Long-term potentiation | 4.42E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Rivastigmine | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
Rivastigmine | hsa04728 | Dopaminergic synapse | 2.08E-03 | 6 | P17612, Q99941, P18848, Q13557, Q13362, P0DP23 | PRKACA, CREBL1, ATF4, CAMK2D, PPP2R5C, CALM1 | More | |
Rivastigmine | hsa04740 | Olfactory transduction | 6.71E-03 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Rivastigmine | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | |
Rivastigmine | hsa04910 | Insulin signaling pathway | 3.62E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Rivastigmine | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
Rivastigmine | hsa04912 | GnRH signaling pathway | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
Rivastigmine | hsa04915 | Estrogen signaling pathway | 2.75E-03 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | |
Rivastigmine | hsa04916 | Melanogenesis | 2.87E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Rivastigmine | hsa04918 | Thyroid hormone synthesis | 1.98E-04 | 5 | P51828, Q99941, P18848, P14625, P02768 | ADCY7, CREBL1, ATF4, HSP90B1, ALB | More | |
Rivastigmine | hsa04921 | Oxytocin signaling pathway | 1.84E-02 | 3 | P0DP23, P17612, Q96RR4 | CALM1, PRKACA, CAMKK2 | More | |
Rivastigmine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | |
Rivastigmine | hsa04924 | Renin secretion | 1.09E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Rivastigmine | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Rivastigmine | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Rivastigmine | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Rivastigmine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Rivastigmine | hsa04932 | Non-alcoholic fatty liver disease | 3.62E-02 | 3 | P49841, Q16718, O14521 | GSK3B, NDUFA5, SDHD | More | |
Rivastigmine | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Rivastigmine | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Rivastigmine | hsa04970 | Salivary secretion | 2.20E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Rivastigmine | hsa04971 | Gastric acid secretion | 2.87E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Rivastigmine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | |
Rivastigmine | hsa04976 | Bile secretion | 1.74E-03 | 4 | O43315, P17612, P08183, Q14032 | AQP9, PRKACA, ABCB1, BAAT | More | |
Rivastigmine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
Rivastigmine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
Rivastigmine | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | |
Rivastigmine | hsa05031 | Amphetamine addiction | 4.18E-04 | 5 | P0DP23, Q13557, P17612, Q99941, P18848 | CALM1, CAMK2D, PRKACA, CREBL1, ATF4 | More | |
Rivastigmine | hsa05034 | Alcoholism | 1.29E-02 | 3 | P17612, P0DP23, Q96RR4 | PRKACA, CALM1, CAMKK2 | More | |
Rivastigmine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | |
Rivastigmine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | |
Rivastigmine | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | |
Rivastigmine | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | |
Rivastigmine | hsa05171 | Coronavirus disease - COVID-19 | 4.36E-05 | 8 | P23396, P62753, P62249, P62906, P27635, Q07020, P46776, P61513 | RPS3, RPS6, RPS16, RPL10A, RPL10, RPL18, RPL27A, RPL37A | More | |
Rivastigmine | hsa05203 | Viral carcinogenesis | 1.46E-02 | 4 | Q99941, P18848, P27348, P61978 | CREBL1, ATF4, YWHAQ, HNRPK | More | |
Rivastigmine | hsa05212 | Pancreatic cancer | 2.87E-02 | 2 | Q15311, P23458 | RALBP1, JAK1 | More | |
Rivastigmine | hsa05215 | Prostate cancer | 4.48E-02 | 2 | P18848, P14625 | ATF4, HSP90B1 | More | |
Rivastigmine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | |
Rivastigmine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |